87 related articles for article (PubMed ID: 19246985)
1. HER1-ECD vaccination dispenses with emulsification to elicit HER1-specific anti-proliferative effects.
Alpízar YA; Ramírez BS; Fernández DR; Capote AR; Hidalgo GG; Rodríguez RP; Molina LE
Hum Vaccin; 2009 Mar; 5(3):158-65. PubMed ID: 19246985
[TBL] [Abstract][Full Text] [Related]
2. Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant.
Ramírez BS; Pestana ES; Hidalgo GG; García TH; Rodríguez RP; Ullrich A; Férnandez LE
Int J Cancer; 2006 Nov; 119(9):2190-9. PubMed ID: 16841332
[TBL] [Abstract][Full Text] [Related]
3. Immuno-toxicological evaluation of her1 cancer vaccine in non-human primates: a 6-month subcutaneous study.
Mancebo Rodríguez A; Bergado Báez G; Acosta Lago E; León Goñi A; Blanco Gámez D; Fuentes Morales D; Hernández Fernández DR; Sánchez Ramírez B; Pérez Barreda A; Casacó Parada Á
Immunopharmacol Immunotoxicol; 2021 Jun; 43(3):283-290. PubMed ID: 33722157
[No Abstract] [Full Text] [Related]
4. Non-clinical immuno-toxicological evaluation of HER1 cancer vaccine in non-human primates: a 12-month study.
Barro AM; Rivero AI; Goñi AL; Navarro BO; Angarica MM; Ramírez BS; Bedoya DM; Triana CG; Rodríguez AM; Parada ÁC
Vaccine; 2012 Dec; 31(1):89-95. PubMed ID: 23142132
[TBL] [Abstract][Full Text] [Related]
5. Effects of an epidermal growth factor receptor-based cancer vaccine on wound healing and inflammation processes in murine experimental models.
Fuentes D; Chacón L; Casacó A; Ledón N; Fernández N; Iglesias A; Hernández DR; Sánchez B; Pérez R
Int Wound J; 2014 Feb; 11(1):98-103. PubMed ID: 22947303
[TBL] [Abstract][Full Text] [Related]
6. Very small size proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer.
Aguilar FF; Barranco JJ; Fuentes EB; Aguilera LC; Sáez YL; Santana MD; Vázquez EP; Baker RB; Acosta OR; Pérez HG; Nieto GG
Vaccine; 2012 Oct; 30(46):6595-9. PubMed ID: 22921738
[TBL] [Abstract][Full Text] [Related]
7. Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine.
Rodriguez PC; Gonzalez I; Gonzalez A; Avellanet J; Lopez A; Perez R; Lage A; Montero E
Vaccine; 2008 Aug; 26(36):4647-54. PubMed ID: 18640164
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates.
Morera Y; Bequet-Romero M; Ayala M; Velazco JC; Pérez PP; Alba JS; Ancizar J; Rodríguez M; Cosme K; Gavilondo JV
Vaccine; 2010 Apr; 28(19):3453-61. PubMed ID: 20197134
[TBL] [Abstract][Full Text] [Related]
9. Anti-EGFR activation, anti-proliferative and pro-apoptotic effects of polyclonal antibodies induced by EGFR-based cancer vaccine.
Ramírez BS; Alpízar YA; Fernández DR; Hidalgo GG; Capote AR; Rodríguez RP; Fernández LE
Vaccine; 2008 Sep; 26(38):4918-26. PubMed ID: 18672015
[TBL] [Abstract][Full Text] [Related]
10. B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR).
Zhu L; Zhao L; Wu M; Chen Z; Li H
Immunol Lett; 2013 Jun; 153(1-2):33-40. PubMed ID: 23871733
[TBL] [Abstract][Full Text] [Related]
11. Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphate.
Pérez Sánchez L; Morera Díaz Y; Bequet-Romero M; Ramses Hernández G; Rodríguez Y; Castro Velazco J; Puente Pérez P; Ayala Avila M; Gavilondo JV
Hum Vaccin Immunother; 2015; 11(8):2030-7. PubMed ID: 25891359
[TBL] [Abstract][Full Text] [Related]
12. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor.
Lu Y; Wei YQ; Tian L; Zhao X; Yang L; Hu B; Kan B; Wen YJ; Liu F; Deng HX; Li J; Mao YQ; Lei S; Huang MJ; Peng F; Jiang Y; Zhou H; Zhou LQ; Luo F
J Immunol; 2003 Mar; 170(6):3162-70. PubMed ID: 12626574
[TBL] [Abstract][Full Text] [Related]
13. The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development.
Huijbers EJ; Femel J; Andersson K; Björkelund H; Hellman L; Olsson AK
Vaccine; 2012 Jan; 30(2):225-30. PubMed ID: 22079080
[TBL] [Abstract][Full Text] [Related]
14. Immunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection.
Cargnelutti DE; Salomón MC; Celedon V; García Bustos MF; Morea G; Cuello-Carrión FD; Scodeller EA
J Microbiol Immunol Infect; 2016 Feb; 49(1):24-32. PubMed ID: 24662018
[TBL] [Abstract][Full Text] [Related]
15. The Immunogenicity and Anti-Tumor Efficacy of a Rationally Designed EGFR Vaccine.
Cheng C; Deng L; Li R
Cell Physiol Biochem; 2018; 46(1):46-56. PubMed ID: 29566364
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
Helguera G; Dela Cruz JS; Lowe C; Ng PP; Trinh R; Morrison SL; Penichet ML
Vaccine; 2006 Jan; 24(3):304-16. PubMed ID: 16125282
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.
Fernández A; Mesa C; Marigo I; Dolcetti L; Clavell M; Oliver L; Fernández LE; Bronte V
J Immunol; 2011 Jan; 186(1):264-74. PubMed ID: 21135171
[TBL] [Abstract][Full Text] [Related]
18. HER1-based vaccine: Simultaneous activation of humoral and cellular immune response.
Bergado Báez G; Hernández Fernández DR; Mazorra Herrera Z; Sánchez Ramírez B
Semin Oncol; 2018 Jan; 45(1-2):75-83. PubMed ID: 30318087
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.
Sánchez Ramírez J; Morera Díaz Y; Bequet-Romero M; Hernández-Bernal F; Selman-Housein Bernal KH; de la Torre Santos A; Santiesteban Álvarez ER; Martín Bauta Y; Bermúdez Badell CH; de la Torre Pupo J; Gavilondo JV; ; Ayala Avila M
BMC Immunol; 2017 Jul; 18(1):39. PubMed ID: 28747172
[TBL] [Abstract][Full Text] [Related]
20. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
